Reviva to Participate in the UBS Global Healthcare Conference
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on central nervous system, inflammatory and cardiometabolic diseases, has announced its participation in the UBS Global Healthcare Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat at the conference, which is scheduled for November 11-14, 2024, in Rancho Palos Verdes, CA. The presentation is specifically scheduled for Thursday, November 14, 2024, at 8:00 a.m. PT.
Reviva Pharmaceuticals (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata focalizzata su patologie del sistema nervoso centrale, infiammatorie e cardiometaboliche, ha annunciato la sua partecipazione alla Conferenza Globale sulla Salute di UBS. Il fondatore, presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., parteciperà a una chiacchierata informale durante la conferenza, che si terrà dal 11 al 14 novembre 2024, a Rancho Palos Verdes, CA. La presentazione è programmata per giovedì 14 novembre 2024, alle 8:00 a.m. PT.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en enfermedades del sistema nervioso central, inflamatorias y cardiometabólicas, ha anunciado su participación en la Conferencia Global de Salud de UBS. El fundador, presidente y CEO de la empresa, Laxminarayan Bhat, Ph.D., participará en una charla informal en la conferencia, que está programada para el 11 al 14 de noviembre de 2024, en Rancho Palos Verdes, CA. La presentación está programada para el jueves 14 de noviembre de 2024, a las 8:00 a.m. PT.
Reviva Pharmaceuticals (NASDAQ: RVPH)는 중추 신경계, 염증 및 심대사 질환에 중점을 둔 후기 단계의 제약 회사로, UBS 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 창립자이자 회장, CEO인 Laxminarayan Bhat 박사가 컨퍼런스에서 대화형 세션에 참여할 예정이며, 이 행사는 2024년 11월 11일부터 14일까지 캘리포니아주 랜초 팔로스 베르데스에서 열립니다. 발표는 2024년 11월 14일 목요일 오전 8:00 PT로 예정되어 있습니다.
Reviva Pharmaceuticals (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée axée sur les maladies du système nerveux central, inflammatoires et cardiométaboliques, a annoncé sa participation à la Conférence Mondiale sur la Santé de UBS. Le fondateur, président et PDG de l'entreprise, Laxminarayan Bhat, Ph.D., participera à une discussion informelle lors de la conférence, qui se déroulera du 11 au 14 novembre 2024 à Rancho Palos Verdes, Californie. La présentation est spécifiquement prévue pour le jeudi 14 novembre 2024 à 8h00 PT.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein Unternehmen in der späten Entwicklungsphase, das sich auf Zentralnervensystem-, Entzündungs- und kardiometabolische Erkrankungen konzentriert, hat seine Teilnahme an der UBS Global Healthcare Conference bekannt gegeben. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird an einem Kamin-Gespräch während der Konferenz teilnehmen, die vom 11. bis 14. November 2024 in Rancho Palos Verdes, Kalifornien, stattfinden wird. Die Präsentation ist speziell für Donnerstag, den 14. November 2024, um 8:00 Uhr PT geplant.
- None.
- None.
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.
UBS Global Healthcare Conference
Format: Fireside chat
Date: Thursday, November 14, 2024
Time: 8:00 a.m. PT
Location: Rancho Palos Verdes, CA
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the UBS Global Healthcare Conference 2024?
What type of presentation will RVPH deliver at the UBS Healthcare Conference?
What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?
Where is the 2024 UBS Global Healthcare Conference being held?
